Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?
Ann Oncol
.
2014 Feb;25(2):303-6.
doi: 10.1093/annonc/mdt488.
Epub 2013 Dec 10.
Authors
L Bergmann
1
,
H Enzmann
,
K Broich
,
A Hebborn
,
S Marsoni
,
L Goh
,
J F Smyth
,
H Zwierzina
Affiliation
1
Medical Clinic II, University Hospital, Frankfurt.
PMID:
24335759
DOI:
10.1093/annonc/mdt488
No abstract available
Publication types
Editorial
MeSH terms
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Drug Screening Assays, Antitumor
Europe
Humans
Neoplasms / drug therapy*
Technology Assessment, Biomedical*
Substances
Antineoplastic Agents